We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
| Name | Symbol | Market | Type |
|---|---|---|---|
| Roche Holdings Ltd AG (QX) | USOTC:RHHBY | OTCMarkets | Depository Receipt |
| Price Change | % Change | Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.57 | 1.95% | 29.83 | 29.78 | 29.86 | 30.08 | 29.715 | 30.04 | 4,829,456 | 21:22:28 |
From May 2021 to May 2024
By Cristina Roca
Roche Holding AG said late Friday that its at-home Covid-19 test has been granted emergency-use authorization by the U.S. Food and Drug Administration and will be available across the country from January.
The Swiss pharmaceutical holding said the kit produces accurate results in as little as 20 minutes for all known variants of concern of the virus, including Omicron.
The test was prioritized by the FDA based on the ability of Roche and SD Biosensor Inc.--with which Roche has a global distribution agreement--to delivery large quantities and increase manufacturing to meet future demand. Roche has the capacity to produce tens of millions of tests a month, it said.
Write to Cristina Roca at cristina.roca@wsj.com
(END) Dow Jones Newswires
December 27, 2021 01:42 ET (06:42 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
1 Year Roche (QX) Chart |
1 Month Roche (QX) Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
